2021 GBM journey --- Exerpts from Abstract: *The

New Post Public Reply Private Reply Replies (0) Message Board
My69z
680
2021 GBM journey ---

Exerpts from Abstract:
*The mechanisms governing therapeutic resistance of the most aggressive and lethal primary brain tumor in adults, glioblastoma, have increasingly focused on tumor stem cells.

*Integrated proteogenomic and metabolomic analyses of glioblastoma tissues and single cells have revealed insights into the complex heterogeneity of glioblastoma and stromal cells, comprising its tumor microenvironment (TME).

An additional factor, which isdriving poor therapy response is the distinct genetic drivers in each patient’s tumor, providing the rationale for a more individualized or personalized approach to treatment.

*CCL5 was not expressed in glioblastoma stem cells, suggesting a need for paracrine activation of CCR5 signaling by the stromal cells.

TME-associated immune cells, such as resident microglia, infiltrating macrophages, T cells, and mesenchymal stem cells, possibly release CCR5 ligands, providing heterologous signaling between stromal and glioblastoma stem cells.

* These “hotlines” of autocrine and paracrine information use similar “molecular hardware” (chemokines, cytokines, growth factors, enzymes, and other signal transmitters) to interconnect complex cellular activities, promoting tumor progression.

Resident and infiltrating immuno-competent cells express a large number of inflammatory mediators supporting GBM aggressiveness and resistance, partially also due to GBM-derived factors that educate them to do so.
___
2.2. Cancer Stem Cells in Glioblastoma

*Moreover, GSCs reportedly transdifferente to pericytes to support GBM angiogenesis and tumor growth [40], thus to some extent also creating their own microenvironment.

Taken together intratumor cellular heterogeneity may be due to GSC cells of different brain cells and diverse dedifferentiation.

Many attempts to develop targeted or tailored therapies for specific mutations or GBM subtypes largely failed due to these complexities and selective inter-GBM molecular cross talk.

* GBMs that evolved from GSCs are the most aggressive brain tumors with an average survival of only 15 months after surgery and chemo-irradiation [1].

* High rates of therapy resistance and GBM recurrence after therapy are due to the GSC plasticity and intercellular heterogeneity resulting from GSC dedifferentiation.

GSC dedifferentiation results from the loss of stemness genes by the progeny of GSCs

2.3. Glioblastoma Therapy

The standard-of-care therapeutic modalities for GBM (including maximally safe surgical resection, irradiation (IR), chemotherapy with alkylating agent temozolomide (TMZ), and frequency electrotherapy of tumor treating fields (TTF) [32] has increased median patient survival from approximately16 months to 20 months after diagnosis.

The high levels of GBM cell outgrowth throughout the brain make surgical resection mostly incomplete and prevent IR from being focused.

Moreover, GSC plasticity, as described above, promotes therapy resistance to a much greater extent than the blood–brain barrier that is mostly compromised in glioblastoma tumors.

Thus, unlike many other cancer types, in which targeted therapies have improved survival substantially, there have not been similar advances in GBM treatment [41].

* The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].

* Secondly, the expression of immune checkpoint proteins, which mediate the direct contact between GBM and cytotoxic CD8+ T cells, such as the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) and cytotoxic T-lymphocyte protein 4 (CTLA-4), can be inhibited by targeted antibodies.

Phase II and III clinical trials are currently assessing anti-hPD-1 and anti-CTLA-4 antibody-based drugs in GBM [82] (see Section 5.2).

*Recent studies have shown functional synergy between the DNA damaging agent, doxorubicin, and the CCR5 inhibitor maraviroc [87,88,92,95,99,119]. DNA damage repair pathways also contribute to the therapeutic resistance of GSCs [2], and therefore, maraviroc and leronlimab are good candidates for adjuvant GBM therapy.

* Autocrine and multicellular paracrine CCL5–CCR interactions represent a new node of cross talk that should be considered as a target for eliminating GBM and GSC activation.

Clinical trials have recently opened targeting CCR5 using a humanized monoclonal antibody (leronlimab) for metastatic triple-negative breast cancer (TNBC) NCT03838367 or a small molecule inhibitor maraviroc for metastatic colon cancer (NCT03631407, NCT03274804).
https://pmc.ncbi.nlm.nih.gov/articles/PMC8123...04464-f001

& look @ the funding sources--- the US & EU know of our GBM.

The Slovenian & Dr. Pestells Hungary cancer commission comes to mind.

Yesterday news is 100% in-line with this publication.

Dr. Pestell after re-joining Cytodyn, took some Leronlimab back to a private corner of Bauch lab, & got to work on this hypothesis.

Jan. 2026 submitted Abstract.

3/23/2026 -- public & ties the entirity of the Leronlimab journey, to justifying pre-dosing GBM surgeries.

Nice !!!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 15

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 35

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 347

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 10

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 87

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

Ragie Launches Advanced Agent Ready Features for Developers

Updated Category News Views 253

Ragie Introduces Innovative Agent Ready Features Ragie is excited to present its latest advancement: the introduction of Agent Ready capabilities. This launch focuses on empowering developers with tools for creating intelligent, context-aware agents. Enhanced features like Agentic Retrieval and support for Right-to-Left (RTL) languages enhance accessibility and robust...

Continue Reading
JNR Stellarc 100K: A Game-Changer in Refillable Vapes

Updated Category News Views 200

Introducing the JNR Stellarc 100K Refillable Vape JNR has officially launched the JNR Stellarc 100K, a remarkable modular refillable vape system that promises to redefine the vaping experience. Engineered for extreme endurance and superior safety features, the Stellarc 100K is set to offer unparalleled value to its users. This advanced vape is not just another product; it...

Continue Reading
Xiao-I Corporation Shareholders Encouraged to Join Class Action

Updated Category News Views 86

Xiao-I Corporation Shareholders Encouraged to Join Class Action Recent events have led to significant concerns for shareholders of Xiao-I Corporation. With allegations of misleading statements and inadequate disclosures surfacing, many shareholders find themselves at a crossroads. It is essential for investors who purchased shares during a specific period to explore their...

Continue Reading
Assessing Bristol Myers Squibb: Analyst Insights and Future Prospects

Updated Category News Views 138

Bristol Myers Squibb: A Low Valuation Opportunity BofA Securities has recently upgraded Bristol Myers Squibb Co. (NYSE: BMY) from a Neutral position to a Buy rating, indicating a positive outlook for the company driven by strong near-term catalysts. Analyst Jason Gerberry highlighted a compelling risk-reward scenario, especially as the company anticipates a flat...

Continue Reading
Carrier's Q3 Performance and Future Outlook: Key Insights

Updated Category News Views 237

Carrier Global Corporation's Q3 Earnings Overview Carrier Global Corporation (NYSE: CARR), a prominent innovator in climate and energy solutions, recently released its third-quarter earnings, showcasing performance that exceeded market expectations. The results highlight not only the financial stability of the company but also the strategic adjustments made to navigate...

Continue Reading